Steven Pieper
CIK: 0001875714
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Xeris Biopharma Holdings, Inc.
Discretionary Trading P&L
Holdings
Transaction History (16 total)
- Oct 1, 2026XERS
Xeris Biopharma Holdings, Inc.
Sale(S)Direct5K shares at avg. $9.41$47K - Sep 1, 2026XERS
Xeris Biopharma Holdings, Inc.
Sale(S)Direct5K shares at avg. $8.50$43K - Aug 12, 2026XERS
Xeris Biopharma Holdings, Inc.
Sale(S)Direct5K shares at avg. $8.50$43K - Jul 7, 2026XERS
Xeris Biopharma Holdings, Inc.
Sale(S)Direct27.6K shares at avg. $8.52$235K - Jul 6, 2026XERS
Xeris Biopharma Holdings, Inc.
Sale(S)Direct17.4K shares at avg. $8.50$148K - Mar 5, 2026XERS
Xeris Biopharma Holdings, Inc.
Exercise(M)Direct14K shares at avg. $5.93$83K - Mar 5, 2026XERS
Xeris Biopharma Holdings, Inc.
Exercise(M)Direct27.9K shares at avg. $4.09$114K - Jan 31, 2026XERS
Xeris Biopharma Holdings, Inc.
Tax Payment(F)Direct111.8K shares at avg. $7.36$823K - Jan 31, 2026XERS
Xeris Biopharma Holdings, Inc.
Tax Payment(F)Direct27.3K shares at avg. $7.36$201K - Jan 31, 2026XERS
Xeris Biopharma Holdings, Inc.
Tax Payment(F)Direct66.5K shares at avg. $7.36$489K - Jan 30, 2026XERS
Xeris Biopharma Holdings, Inc.
Award(A)Direct155K shares- - Jan 31, 2025XERS
Xeris Biopharma Holdings, Inc.
Tax Payment(F)Direct66.5K shares at avg. $3.56$237K - Jan 31, 2025XERS
Xeris Biopharma Holdings, Inc.
Award(A)Direct185K shares- - Jan 31, 2025XERS
Xeris Biopharma Holdings, Inc.
Tax Payment(F)Direct110.8K shares at avg. $3.56$394K - Jan 3, 2025XERS
Xeris Biopharma Holdings, Inc.
Tax Payment(F)Direct32.1K shares at avg. $3.61$116K - Nov 22, 2024XERS
Xeris Biopharma Holdings, Inc.
Exercise(M)Direct19.5K shares at avg. $1.55$30K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 1, 2026 | XERS Xeris Biopharma Holdings, Inc. | Sale(S) | 5,000 | $9.41 | $47,037 | Direct |
| Sep 1, 2026 | XERS Xeris Biopharma Holdings, Inc. | Sale(S) | 5,000 | $8.50 | $42,500 | Direct |
| Aug 12, 2026 | XERS Xeris Biopharma Holdings, Inc. | Sale(S) | 5,000 | $8.50 | $42,500 | Direct |
| Jul 7, 2026 | XERS Xeris Biopharma Holdings, Inc. | Sale(S) | 27,600 | $8.52 | $235,276 | Direct |
| Jul 6, 2026 | XERS Xeris Biopharma Holdings, Inc. | Sale(S) | 17,400 | $8.50 | $147,900 | Direct |
| Mar 5, 2026 | XERS Xeris Biopharma Holdings, Inc. | Exercise(M) | 14,036 | $5.93 | $83,233 | Direct |
| Mar 5, 2026 | XERS Xeris Biopharma Holdings, Inc. | Exercise(M) | 27,891 | $4.09 | $114,074 | Direct |
| Jan 31, 2026 | XERS Xeris Biopharma Holdings, Inc. | Tax Payment(F) | 111,765 | $7.36 | $822,590 | Direct |
| Jan 31, 2026 | XERS Xeris Biopharma Holdings, Inc. | Tax Payment(F) | 27,319 | $7.36 | $201,068 | Direct |
| Jan 31, 2026 | XERS Xeris Biopharma Holdings, Inc. | Tax Payment(F) | 66,450 | $7.36 | $489,072 | Direct |
| Jan 30, 2026 | XERS Xeris Biopharma Holdings, Inc. | Award(A) | 154,986 | - | $0 | Direct |
| Jan 31, 2025 | XERS Xeris Biopharma Holdings, Inc. | Tax Payment(F) | 66,450 | $3.56 | $236,562 | Direct |
| Jan 31, 2025 | XERS Xeris Biopharma Holdings, Inc. | Award(A) | 185,000 | - | - | Direct |
| Jan 31, 2025 | XERS Xeris Biopharma Holdings, Inc. | Tax Payment(F) | 110,750 | $3.56 | $394,270 | Direct |
| Jan 3, 2025 | XERS Xeris Biopharma Holdings, Inc. | Tax Payment(F) | 32,059 | $3.61 | $115,733 | Direct |
| Nov 22, 2024 | XERS Xeris Biopharma Holdings, Inc. | Exercise(M) | 19,483 | $1.55 | $30,199 | Direct |
1-16 of 16 transactions
About Pieper Steven
Pieper Steven (SEC CIK 0001875714) files insider reports with the SEC as Officer of Xeris Biopharma Holdings, Inc. (XERS).
Signal8 holds 9 ownership filings by Pieper Steven, all Form 4s, filed between Nov 26, 2024 and Oct 2, 2026. Those filings report 16 transactions, from Nov 22, 2024 to Oct 1, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Pieper Steven's filings is in CHICAGO, IL.
Recent filings by Pieper Steven
- Oct 1, 2026: Open-market sale of XERS shares (Form 4, code S).
- Sep 1, 2026: Open-market sale of XERS shares (Form 4, code S).
- Aug 12, 2026: Open-market sale of XERS shares (Form 4, code S).
- Jul 7, 2026: Open-market sale of XERS shares (Form 4, code S).
- Jul 6, 2026: Open-market sale of XERS shares (Form 4, code S).
Other insiders filing for Xeris Biopharma Holdings, Inc. (XERS)
- McCulloch Kevin
- Hecht Beth
- Shannon John Patrick Jr
- KREHER NERISSA, Director
- Kong Garheng, Director
- PERSKY MARLA, Director